We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.57%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.86B
AUM Growth
-$642M
Cap. Flow
-$108M
Cap. Flow %
-2.23%
Top 10 Hldgs %
44.28%
Holding
142
New
24
Increased
23
Reduced
21
Closed
24

Top Buys

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$127M
2
EW icon
Edwards Lifesciences
EW
+$80.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$78.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$43.5M
5
CYTK icon
Cytokinetics
CYTK
+$42.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$81.3M
2
ELV icon
Elevance Health
ELV
+$55.2M
3
BIIB icon
Biogen
BIIB
+$51.3M
4
MRK icon
Merck
MRK
+$50.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$124B
$60.8M 1.25%
151,000
– –
THRD
27
DELISTED
Third Harmonic Bio
THRD
$59.5M 1.22%
5,779,071
– –
CRNX icon
28
Crinetics Pharmaceuticals
CRNX
$8.88B
$51.1M 1.05%
999,000
-51,055
-5% -$2.86M
UHS icon
29
Universal Health Services
UHS
$10.1B
$48.3M 0.99%
269,300
+113,300
+73% +$23.1M
SIBN icon
30
SI-BONE Inc
SIBN
$804M
$48.3M 0.99%
3,442,853
+137,052
+4% +$1.84M
SWTX
31
DELISTED
SpringWorks Therapeutics
SWTX
$45.3M 0.93%
1,255,031
-135,600
-10% -$4.74M
TMO icon
32
Thermo Fisher Scientific
TMO
$215B
$43.9M 0.9%
84,400
– –
TERN
33
DELISTED
Terns Pharmaceuticals
TERN
$41.9M 0.86%
7,562,971
– –
CGON icon
34
CG Oncology
CGON
$6.04B
$41M 0.84%
1,431,114
+740,000
+107% +$25.3M
JANX icon
35
Janux Therapeutics
JANX
$902M
$40.6M 0.84%
758,566
-500,000
-40% -$26.4M
EXAS
36
DELISTED
Exact Sciences
EXAS
$38.2M 0.79%
679,816
– –
NPCE icon
37
Neuropace
NPCE
$490M
$38.1M 0.78%
3,406,335
– –
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.22B
$37.2M 0.76%
947,877
+36,457
+4% +$1.51M
CRVS icon
39
Corvus Pharmaceuticals
CRVS
$1.1B
$37.1M 0.76%
6,943,654
– –
XBI icon
40
State Street SPDR S&P Biotech ETF
XBI
$10B
$33.5M 0.69%
+372,000
New +$36M
CMPX icon
41
Compass Therapeutics
CMPX
$358M
$32.4M 0.67%
22,362,850
– –
XTNT icon
42
Xtant Medical Holdings
XTNT
$59.1M
$32.4M 0.67%
73,114,592
– –
RNAM
43
DELISTED
Avidity Biosciences
RNAM
$32.4M 0.67%
1,112,886
+68,081
+7% +$2.85M
VERA icon
44
Vera Therapeutics
VERA
$2.33B
$31.4M 0.65%
742,572
+66,700
+10% +$2.95M
DYN icon
45
Dyne Therapeutics
DYN
$4.2B
$28.9M 0.59%
1,227,080
+518,680
+73% +$15.3M
CGEM icon
46
Cullinan Oncology
CGEM
$1.04B
$23.7M 0.49%
1,942,555
+872,500
+82% +$12.5M
VIR icon
47
Vir Biotechnology
VIR
$1.47B
$23.6M 0.49%
3,218,617
-354,383
-10% -$2.8M
GILD icon
48
Gilead Sciences
GILD
$166B
$22.7M 0.47%
245,600
+93,900
+62% +$8.45M
RYTM icon
49
Rhythm Pharmaceuticals
RYTM
$7.39B
$22.4M 0.46%
400,000
-35,900
-8% -$1.98M
IMTX icon
50
Immatics
IMTX
$1.18B
$22M 0.45%
3,087,462
+1,081,081
+54% +$9.29M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2024 Portfolio in Review

As of Q4 2024, OrbiMed held 142 positions worth $4.86B, down 12% from $5.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed's Q4 2024 filing shows 24 new, 23 increased, 21 reduced and 24 closed positions. Its largest new stake was Upstream Bio Inc: 5,693,589 shares worth $93.6M. The largest sale was Amgen, an estimated $81.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • OrbiMed's largest Q4 2024 buy was Upstream Bio Inc: 5,693,589 shares worth $93.6M.
  • OrbiMed added most to Neurocrine Biosciences in Q4 2024, an estimated $78.7M increase.
  • OrbiMed's biggest Q4 2024 reduction was Biogen, cutting an estimated $51.3M.
  • OrbiMed fully exited Amgen in Q4 2024, selling an estimated $81.3M.
  • OrbiMed's ten largest holdings make up 44% of its $4.86B portfolio in Q4 2024.
  • OrbiMed opened 24 new positions and closed 24 in Q4 2024.
  • OrbiMed's portfolio value fell 12% quarter-over-quarter to $4.86B.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.